Reply to “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma”

Clinical and Molecular Hepatology, Journal Year: 2025, Volume and Issue: 31(2), P. e208 - e209

Published: Jan. 7, 2025

Language: Английский

Real‐world efficacy and safety of universal 8‐week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre‐end‐stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan

The Kaohsiung Journal of Medical Sciences, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 19, 2025

Abstract An 8‐week regimen of glecaprevir/pibrentasvir is recommended for treatment‐naïve patients with chronic hepatitis C (CHC). In alignment the Taiwanese government's objective to eliminate by 2025, this study aimed provide real‐world evidence on use in kidney disease (CKD) using data from Taiwan Association Study Liver HCV Registry (TACR). CKD was defined an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 or higher proteinuria persisting over 3 months. Patients were categorized as having early (eGFR ≥45 ) pre‐end‐stage renal (pre‐ESRD) <45 ). Among 1072 who received at least one dose regimen, 1054 had available assessing sustained virologic response 12 weeks posttreatment (SVR12). The overall SVR12 99.6%, rates 99.7% pre‐ESRD and 99.6% patients. Subgroup analysis showed 100% efficacy genotype dyslipidemia, 99.5% diabetes, 99.4% cardiovascular disease, 96.9% a history cerebral vascular accident, 95.5% drug injection HIV co‐infection. Adverse events reported 16.8% patients, 0.8% experiencing serious events, only two cases treatment‐related. Renal function significantly improved, eGFR increasing 39.2 41.9 . Early rise 53.5 57.1, while improved 27.1 29.2 SVR12. concluded that highly effective, well‐tolerated, associated significant improvement CHC both pre‐ESRD.

Language: Английский

Reply to comment on “Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program”

Journal of the Formosan Medical Association, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский